The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor

BACKGROUND: Sodium–glucose cotransporter 2 inhibitor (SGLT2i) use reduces body weight (BW) in patients with type 2 diabetes mellitus (T2DM). Obesity and T2DM are strong risk factors of new-onset atrial fibrillation (AF). However, whether BW loss following SGLT2i treatment reduces AF risk in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Yi-Hsin, Chen, Shao-Wei, Chao, Tze-Fan, Kao, Yi-Wei, Huang, Chien-Ying, Chu, Pao-Hsien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091721/
https://www.ncbi.nlm.nih.gov/pubmed/33941171
http://dx.doi.org/10.1186/s12933-021-01285-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091721/
https://www.ncbi.nlm.nih.gov/pubmed/33941171
http://dx.doi.org/10.1186/s12933-021-01285-8

Ejemplares similares